SOLANA BEACH, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced today that it has closed an underwritten public offering led by Nantahala Capital Management, with participation by other fundamental investors, for gross proceeds of up to $30 million, which included an initial upfront funding of approximately $7.5 million, prior to deducting underwriting discounts and commissions and estimated offering expenses.

加利福尼亚州索拉纳海滩，2024年2月14日（环球通讯社）--Evoke Pharma，Inc.（纳斯达克：EVOK），一家专业制药公司，主要专注于胃肠道（GI）疾病的治疗，重点是GIMOTI®（甲氧氯普胺）鼻喷雾剂，今天宣布它已经结束了由南塔哈拉资本管理公司牵头的承销公开发行，在其他基本面投资者的参与下，总收益高达3000万美元，其中包括约750万美元的初始前期资金，然后再扣除承销折扣和佣金以及估计的发行费用。

'We are pleased to have closed this offering with these fundamental, healthcare-oriented institutional investors,' stated Evoke Pharma Chief Executive Officer Dave Gonyer. 'With the momentum we're experiencing in new prescribers and prescriptions and our continued capital efficient infrastructure, we expect that, based on our current operating plan, our existing cash and cash equivalents, future cash flows from net product sales, along with the initial net proceeds from this offering should be sufficient to fund our operations for the next 12 months.

Evoke Pharma首席执行官戴夫·戈尼尔（DaveGonyer）表示，我们很高兴能够与这些基本的、以医疗保健为导向的机构投资者完成此次发售随着我们在新处方和处方方面的发展势头以及我们持续的资本高效基础设施，我们预计，根据我们目前的运营计划，我们现有的现金和现金等价物，未来净产品销售产生的现金流，以及本次发行的初始净收益，应该足以为我们未来12个月的运营提供资金。

The combination of new commercial programs and distribution gives us the confidence to continue to gain new GIMOTI prescribers and increase prescriptions, fills, and revenue of GIMOTI with the goal of attaining profitability for the company. We are committed to driving long-term shareholder value, and we believe that honing in on our current strategies and being capital efficient will allow us to operate a sustainable, profitable specialty pharmaceutical business.' The offering was comprised of (i) 11,029,411 shares of common stock (or pre-funded warrants in lieu thereof), (ii) 11,029,411 Series A Warrants with an initial .

新的商业计划和分销的结合使我们有信心继续获得新的GIMOTI处方，并增加GIMOTI的处方，填充和收入，以实现公司盈利的目标。我们致力于推动股东的长期价值，我们相信，磨练我们目前的战略，提高资本效率，将使我们能够经营一个可持续、盈利的专业制药业务。”本次发行包括（i）11029411股普通股（或替代普通股的预供认股权证），（ii）11029411股A系列认股权证，首次发行。